Screener
Crinetics Pharmaceuticals CRNX Business Segments — Early Research and Development Programs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:EarlyResearchAndDevelopmentPrograms.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Research and development | ||
| Paltusotine | (11,869) | (17,251) |
| Atumelnant | (20,267) | (7,749) |
| Other research and development programs | (9,667) | (7,058) |
| Research and development personnel expenses | (30,649) | (25,627) |
| Research and development stock-based compensation | (19,328) | (11,819) |
| Other research and development (1) | (8,301) | (6,736) |
| Total research and development expenses | (100,081) | (76,240) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's business segments — early research and development programs?
- Crinetics Pharmaceuticals (CRNX) reported business segments — early research and development programs of $9.67M in Q1 2026.
- What does business segments — early research and development programs mean?
- This metric aggregates the costs associated with the company's discovery-stage and early-pipeline research initiatives. It represents the investment in future growth drivers that have not yet reached advanced clinical development. This figure highlights the company's commitment to long-term innovation and pipeline replenishment.
Ask your AI about Crinetics Pharmaceuticals's business segments — early research and development programs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude